Form 4: Neumora Therapeutics Director's Stock Options Repriced Following Shareholder Approval

Neumora Therapeutics, Inc. director Matthew K. Fust's stock options were repriced to an exercise price of $0.72 per share after shareholder approval on May 28, 2025, contingent on continued service.

Summary

• Matthew K. Fust, a Director of Neumora Therapeutics, Inc. (NMRA), reported changes in his beneficial ownership of derivative securities (stock options) via a Form 4 filing.
• On May 28, 2025, the company's stockholders approved the repricing of outstanding stock options held by Board members, including Mr. Fust, and other service providers.
• The exercise price for 141,959 shares subject to options was reduced from $1.69 per share to $0.72 per share. This includes 85,586 options expiring 04/23/2031, 27,802 options expiring 09/14/2033, and 28,571 options expiring 06/13/2034.
• Additionally, Mr. Fust acquired 80,000 new stock options with an exercise price of $0.72 per share, which are set to expire on May 27, 2035.
• The effectiveness of the repricing is contingent on Mr. Fust remaining in service to Neumora Therapeutics through August 13, 2026.

Sentiment

Score: 4

Explanation: The repricing of stock options, while beneficial for the option holder, typically indicates a significant decline in the company's stock price, which is a negative signal for investors. The new grant and retention clause offer some positive incentive alignment, but the underlying reason for repricing is usually unfavorable, reflecting past underperformance.

Positives

• The stock option repricing to a lower exercise price ($0.72 from $1.69) directly benefits the option holders, including the director, by making the options more 'in-the-money' and restoring their incentive value.
• Shareholder approval of the repricing indicates a formal endorsement of the company's compensation strategy by its owners.
• The grant of an additional 80,000 stock options at the repriced exercise price further incentivizes the director and aligns their interests with potential future stock appreciation.

Negatives

• Stock option repricing often implies that the company's stock price has significantly declined, rendering previous options underwater, which is generally a negative signal for existing shareholders.
• Repricing can be viewed as dilutive to existing shareholder value if it leads to more options being exercised at a lower price than originally anticipated.
• The contingency of continued service for the repricing to be effective ties the director to the company for a specific period, which could be seen as a constraint.

Risks

• The necessity of repricing options suggests that the company's stock price has underperformed, potentially indicating underlying business challenges or negative market sentiment.
• If the director does not remain in service through August 13, 2026, the repricing may not be effective, posing a retention risk for the company.
• The repricing could be perceived negatively by some investors as a sign of poor past performance or a lack of confidence in the stock's ability to recover to previous highs without such adjustments.

Future Outlook

The repricing of options and new grants are designed to re-incentivize key personnel, including directors, by aligning their compensation more closely with current stock performance and future growth potential. This strategy, contingent on continued service, suggests a focus on retention and long-term commitment from the board and key service providers, aiming to motivate them despite past stock price challenges.

Management Comments

• "On May 28, 2025, the Issuer's stockholders approved the repricing of the option."
• "On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share... of the outstanding stock options held by members of the Board, certain employees and other service providers."
• "The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026."

Industry Context

Stock option repricing is a common practice in industries, particularly biotechnology and early-stage growth companies, where stock prices can experience significant volatility or decline. When existing options become 'underwater' (exercise price is higher than current market price), they lose their incentive value. Repricing aims to restore this value, retain talent, and re-align employee and director incentives with the company's current valuation and future growth prospects.

Comparison to Industry Standards

• Repricing of stock options is a recognized, albeit sometimes controversial, compensation strategy employed by companies across various sectors, especially in biotech and technology, when stock values decline significantly.
• Companies like **Moderna (MRNA)** or **BioNTech (BNTX)**, while larger and more established, have also navigated periods of stock volatility where similar compensation adjustments might be considered, though their specific approaches could differ based on scale and maturity.
• Smaller, clinical-stage biotech firms, which often rely heavily on equity compensation to attract and retain specialized talent, frequently utilize repricing as a tool to maintain incentive effectiveness during challenging market conditions.
• The inclusion of a continued service condition (through August 13, 2026) is a standard practice in such repricing agreements, ensuring that the enhanced incentive is tied to ongoing commitment and performance.

Corporate Governance

Stakeholder Impact

• Shareholders: May experience dilution from lower exercise price options; benefit from re-incentivized management; receive a negative signal regarding past stock performance.
• Employees/Service Providers: Those with underwater options benefit from repricing, restoring the incentive value of their equity compensation.
• Management/Directors: Receive a direct financial benefit from repriced options and new grants, contingent on their continued service to the company.

Next Steps

• The reporting person (Matthew K. Fust) must remain in service to Neumora Therapeutics through August 13, 2026, for the repricing to be effective.
• The 80,000 newly granted stock options will vest on the earlier of the one-year anniversary of May 28, 2025, or immediately prior to the next Annual Meeting following May 28, 2025.
• The 28,571 stock options will vest on the earlier of the one-year anniversary of June 13, 2024, or immediately prior to the next Annual Meeting following June 13, 2024.

Key Dates

Recommendation

Keywords

Neumora Therapeutics, NMRA, SEC Form 4, Stock Options, Option Repricing, Director Compensation, Beneficial Ownership, Equity Compensation, Shareholder Approval, Insider Transaction